From: Citibank, N.A.Letter Agreement • February 12th, 2019 • Tabula Rasa HealthCare, Inc. • Services-business services, nec
Contract Type FiledFebruary 12th, 2019 Company IndustryTo: Tabula Rasa HealthCare, Inc. 228 Strawbridge Drive, Suite 100 Moorestown, NJ 08057 Attention: Chief Financial Officer Telephone No.: Facsimile No.: (856) 273-0254 (with such fax to be confirmed by telephone to (888) 974-2763, extension: )
Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5th Floor New York, NY 10036Letter Agreement • February 14th, 2014 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations
Contract Type FiledFebruary 14th, 2014 Company IndustryThe definitions and provisions contained in the 2002 ISDA Equity Derivatives Definitions (the “Equity Definitions”), as published by the International Swaps and Derivatives Association, Inc. (“ISDA”) are incorporated into this Confirmation. In the event of any inconsistency between the Equity Definitions and this Confirmation, this Confirmation shall govern. Certain defined terms used herein are based on terms that are defined in the Prospectus dated November 6, 2013, as supplemented by the Prospectus Supplement dated February 11, 2014 (as so supplemented, the “Prospectus”) relating to the Convertible Senior Notes due 2019 (as originally issued by Counterparty, the “Convertible Notes” and each USD 1,000 principal amount of Convertible Notes, a “Convertible Note”) issued by Counterparty in an aggregate initial principal amount of USD 175,000,000 (as increased by up to an aggregate principal amount of USD 25,000,000 if and to the extent that the Underwriters (as defined herein) exercises
JPMorgan Chase Bank, National Association London Branch Canary Wharf London E14 5JP EnglandLetter Agreement • February 14th, 2014 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations
Contract Type FiledFebruary 14th, 2014 Company IndustryThe definitions and provisions contained in the 2002 ISDA Equity Derivatives Definitions (the “Equity Definitions”), as published by the International Swaps and Derivatives Association, Inc. (“ISDA”) are incorporated into this Confirmation. In the event of any inconsistency between the Equity Definitions and this Confirmation, this Confirmation shall govern. Certain defined terms used herein are based on terms that are defined in the Prospectus dated November 6, 2013, as supplemented by the Prospectus Supplement dated February 11, 2014 (as so supplemented, the “Prospectus”) relating to the Convertible Senior Notes due 2019 (as originally issued by Counterparty, the “Convertible Notes” and each USD 1,000 principal amount of Convertible Notes, a “Convertible Note”) issued by Counterparty in an aggregate initial principal amount of USD 175,000,000 (as increased by up to an aggregate principal amount of USD 25,000,000 if and to the extent that the Underwriters (as defined herein) exercises
RBC Capital Markets, LLC 3 World Financial Center 200 Vesey Street New York, New York 10281 Telephone: (212) 858-7000Letter Agreement • February 14th, 2014 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations
Contract Type FiledFebruary 14th, 2014 Company IndustryThe definitions and provisions contained in the 2002 ISDA Equity Derivatives Definitions (the “Equity Definitions”), as published by the International Swaps and Derivatives Association, Inc. (“ISDA”) are incorporated into this Confirmation. In the event of any inconsistency between the Equity Definitions and this Confirmation, this Confirmation shall govern. Certain defined terms used herein are based on terms that are defined in the Prospectus dated November 6, 2013, as supplemented by the Prospectus Supplement dated February 11, 2014 (as so supplemented, the “Prospectus”) relating to the Convertible Senior Notes due 2019 (as originally issued by Counterparty, the “Convertible Notes” and each USD 1,000 principal amount of Convertible Notes, a “Convertible Note”) issued by Counterparty in an aggregate initial principal amount of USD 175,000,000 (as increased by up to an aggregate principal amount of USD 25,000,000 if and to the extent that the Underwriters (as defined herein) exercises
JPMorgan Chase Bank, National Association London Branch 25 Bank Street Canary Wharf London E14 5JP EnglandLetter Agreement • February 14th, 2014 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations
Contract Type FiledFebruary 14th, 2014 Company IndustryTo: AMAG Pharmaceuticals, Inc. 1100 Winter Street Waltham, Massachusetts 02451 Attention: Mr. Frank E. Thomas: Executive Vice President, Chief Operating Officer Telephone No.: (617) 498-3377 Facsimile No.: (617) 588-0475
RBC Capital Markets, LLC 3 World Financial Center 200 Vesey Street New York, New York 10281 Telephone: (212) 858-7000 February 13, 2014Letter Agreement • February 14th, 2014 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations
Contract Type FiledFebruary 14th, 2014 Company IndustryTo: AMAG Pharmaceuticals, Inc. 1100 Winter Street Waltham, Massachusetts 02451 Attention: Mr. Frank E. Thomas: Executive Vice President, Chief Operating Officer Telephone No.: (617) 498-3377 Facsimile No.: (617) 588-0475
Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5th Floor New York, NY 10036Letter Agreement • February 14th, 2014 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations
Contract Type FiledFebruary 14th, 2014 Company IndustryTo: AMAG Pharmaceuticals, Inc. 1100 Winter Street Waltham, Massachusetts 02451 Attention: Mr. Frank E. Thomas: Executive Vice President, Chief Operating Officer Telephone No.: (617) 498-3377 Facsimile No.: (617) 588-0475